NRx Pharmaceuticals, Inc. (NRXP) Research
NRx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm focused on developing innovative therapies for disorders of the central nervous system and critical lung diseases. Its product portfolio features ZYESAMI, an experimental medication that has successfully completed Phase IIb/III clinical trials for treating respiratory failure associated with COVID-19. Additionally, the company is advancing NRX-100 and NRX-101, a pair of oral therapeutics designed to address bipolar depression, specifically in patients exhibiting acute or sub-acute suicidal thoughts and behaviors. Established in 2015, NRx Pharmaceuticals is headquartered in Wilmington, Delaware.
Market snapshot
- Symbol
- NRXP
- Price
- $3.97
- Day change
- -0.25%
- Market cap
- $68.6M
- P/E ratio
- -5.23x
- 52-week range
- 1.62-5.055
- Sector
- Healthcare
- Industry
- Biotechnology
- Next earnings
- in 2 months
- Analyst price target
- $2.00
Recent news
- NRx Pharmaceuticals Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) will release earnings for its first quarter before the opening bell on Monday, May 18.
- NRx Pharmaceuticals Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call
NRx Pharma (NRXP) set to release Q1 earnings on May 18. Analysts expect $19.43 million in revenue, with a loss of 11 cents per share. FDA clearance received for clinical trial.
Peer companies
Recent insider activity
- Casper Joseph Michael — A-Award (100000 shares) on 2026-01-27
- Casper Joseph Michael — trade (100000 shares) on 2026-01-27
- Javitt Jonathan C — A-Award (125000 shares) on 2025-04-09
- McBride Dennis — A-Award (25000 shares) on 2025-04-09
- Hurvitz Chaim — A-Award (25000 shares) on 2025-04-09
Open NRx Pharmaceuticals, Inc. (NRXP) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.